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Abstract 
The purpose of this study was to determine the role of protein kinase C (PKC) isozymes in carbachol-induced protein secretion in the lacrimal 
gland. Three isoforms of PKC are present in rat lacrimal gland: PKC-a, -6 and -E. Carbachol translocated PKC-E during 5 s incubation. Pretreatment 
with PdBu for 0 to 4 h down-regulated PKC-a by 31% at 20 min, PKC-& by 36% at 2 h, and PKCd by 37% at 4 h. A 2 h phorbol ester treatment 
inhibited carbachol-induced secretion completely at 1 min and partially at 5, and 20 mitt, but did not alter the carbachol-induced increase in the 
intracellular [Ca*‘]. We conclude that PKC-a and -E, but not PKCd, are implicated in cholinergic agonist-induced protein secretion in rat lacrimal 
gland. 
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1. Introduction 
In most secretory tissues studied, cholinergic agonists 
act by producing 1,4,5-inositol trisphosphate (IP,) and 
diacylglycerol from phosphatidylinositol bisphosphate 
[l]. IP, subsequently causes the release of intracellular 
Ca2’ (Ca”) to stimulate secretion, whereas diacylglycerol 
activates PKC to stimulate secretion [1,2]. In the lacrimal 
gland, cholinergic agonists are effective stimuli of protein 
secretion, Ca2’-dependent ion channels, and electrolyte 
and water secretion [3-51. In lacrimal gland acini, cholin- 
ergic agonists cause a rapid production of IP,, which 
mobilizes Ca*+, causing its rapid increase [6]. Then IP,, 
perhaps with inositol 1,3,4,5tetrakisphosphate, causes 
an influx of extracellular Ca2’ (Ca’,‘), which sustains a 
plateau of elevated [Ca”] . To determine the role of Ca2’, 
Quin 2 was used to prevent the cholinergic agonist-stim- 
ulated increase in Ca2’. Chelation of Ca2’ completely in- 
hibited the rapid, transient phase of protein secretion 
and partially (about 60%) inhibited the slower, sustained 
phase [7]. The rapid phase of cholinergic-stimulated pro- 
tein secretion appears to be dependent upon Ca2:, and the 
slower phase partially dependent upon influx of Ca’z. 
Sustained protein secretion appears to be dependent 
upon a different, second mediator. PKC seems a likely 
candidate for the second mediator because the PKC acti- 
vator diacylglycerol is produced concomitantly with IP,. 
PKC was originally described as a Ca” and phospho- 
lipid-dependent kinase activated by diacylglycerol 
produced by the receptor-mediated breakdown of 
phosphoinositides [S]. Molecular cloning and biochemi- 
cal techniques have shown that PKC is a family of closely 
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related enzymes consisting of at least eleven different 
isozymes. The PKC family has been divided into three 
categories [9]. A first group termed classical PKCs in- 
cluding PKC- 01, -/?I, $11 and -y isozymes have a Ca” 
and phospholipid-dependent kinase and phorbol ester 
binding activities. A second group termed new PKCs 
including PKC-E, -6, -8, q, and p [lo] isoforms are Ca*‘- 
independent and phospholipid-stimulated kinases. And 
a third group termed atypical PKCs including PKC-C, 
and -d isoforms are Ca2’ and phospholipid-independent 
kinases. 
The rat lacrimal gland contains three isoforms of 
PKC: PKC-a, -6, and -E [ 11,121. There is evidence sug- 
gesting that PKC might be involved in the mechanisms 
regulating protein secretion in the lacrimal gland. First, 
the 48 isomer, but not the inactive 4a isomer, of phorbol 
12,13-dibutyrate (PdBu) and phorbol 12-myristate 13- 
acetate (PMA), stimulate protein secretion in a time- and 
concentration-dependent manner [ 13,141. Second, the di- 
acylglycerol analog 1-oleoyl 2-acetyl-sn-glycerol also 
stimulates protein secretion [14]. Third, cholinergic ag- 
onists cause a transient, although not significant, de- 
crease in cytosolic PKC activity [7]. A direct role, how- 
ever, for PKC or its individual isozymes in cholinergic 
activation of lacrimal gland cells has not yet been dem- 
onstrated. Furthermore, a recent study [12] suggested 
that PKC might not be the sole effector of phorbol esters 
in inducing protein secretion because three PKC inhib- 
itors did not block phorbol ester-induced protein secre- 
tion. 
In the present study, we used phorbol ester treatment 
to down-regulate PKC isozymes to determine the relative 
role of PKC isozymes in mediating protein secretion in 
response to cholinergic agonists. Our results show that 
PKC-ol is the most sensitive to down-regulation and that 
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this isoform along with PKC-e, but not PKC-6, seems to 
play a major role in cholinergic-induced protein secre- 
tion in the lacrimal gland. 
2. Materials and methods 
2.1. Materials 
PKC-e specific polyclonal antibody was a gift from Dr. Peter Parker 
(Ludwig Institute for Cancer Research, London). Upon commercial 
availability, polyclonal antibodies to PKC-a, -J, and -e were obtained 
from Calbiochem (San Diego, CA) and Gibco BRL (Grand Island, 
NY). Fura-2 tetra-acetoxymethyl esters and Pluronic F127 were ob- 
tained from Molecular Probes (Eugene, OR); PdBu and PMA from LC 
Services (Waltham, MA); phosphatidylserine from Avanti Polar Lipids 
(Pelham, AL); [7-~2P]ATP from ICN Radiochemicals (Irvine, CA); 
CLSPA collagenase from Worthington Biochemical (Freehold, N J); 
Protoblot (Western blot AP system) from Promega (Madison, WI); and 
Protein Kinase C Enzyme Assay System from Amersham (Arlington 
Heights, 1L). 
2.2. Methods 
2.2.1. Preparation of lacrimal gland acini and down-regulation of 
PKC. Both exorbital lacrimal glands were removed from male Wistar 
rats that had been anesthetized with CO 2 for 1 min and then decapi- 
tated. Dispersed acini were isolated by collagenase digestion as de- 
scribed previously [4]. 
The isolated acini were preincubated with or without PdBu (1 pM) 
for 0, 20 min, 2 h, and 4 h at 37°C. To determine if PdBu treatment 
down-regulated PKC, total PKC activity was measured as described in
section 2.2.4. in acini preincubated with or without PdBu for 2 h. In 
addition, peroxidase s cretion was measured inacini preincubated with 
or without PdBu for 2 h. Acini were centrifuged at50 × g for 30 s and 
rechallenged with PdBu (1/tM) for 0 or 20 min. Peroxidase secretion 
was measured as described in section 2.2.2. 
To determine loss of specific isozymes with time, acini preincubated 
with PdBu for 0-4 h were centrifuged at 50 × g for 30 s and homoge- 
nized in buffer containing 30 mM Tris-HCl (pH 7.5), 10 mM EGTA, 
5 mM EDTA, 1 mM dithiothreitol, and 250 mM sucrose. Amount of 
each isozyme was determined by electrophoresis and immunoblotting 
as described below. 
2.2.2. Measurement of[ Cae+]i and peroxidase secretion. Acini were 
incubated in Krebs-Ringer buffer (KRB) containing 1% bovine serum 
albumin, 0.5/tM fura-2 tetra-acetoxymethyl ester, 10% Pluronic F127, 
and 50 #M probenicid for 60 min at 22°C. The cells were then washed, 
and fluorescence was measured at 22°C. Fluorescence was measured 
at excitation wavelengths of 340 and 380 nm as previously described 
[7]. 
To measure peroxidase cretion, acini were incubated for 0 to 20 min 
at a final volume of l ml in KRB buffer containing agonists. To 
terminate incubation, acini were centrifuged. Peroxidase secretion was 
measured in duplicate in the supernatant, using a modification of the 
method of Herzog and Fahimi [15]. The total amount of cellular protein 
in each tube was measured using the method of Bradford. 
2.2.3. Protein kinase C assay. Acini preincubated with or without 
PdBu were centrifuged at50 x g for 30 s. The pellet was homogenized 
at 0°C with a Dounce glass homogenizer in buffer containing 20 mM 
Tris-HC1 (pH 7.5), 2 mM dithiothreitol, 1 pg/ml phosphoramidone, 
0.01% leupeptin, 0.28 pM phenylmethylsulfonyl fluoride, 5 mM EDTA, 
and 10 mM EGTA. The homogenate was stored in 50% glycerol over- 
night at - 20°C. PKC activity was assayed using the Protein Kinase C 
Enzyme Assay System and by determining 32p incorporation i to a 
synthetic octapeptide NHz-Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu, which 
is phosphorylated by all PKC isozymes. Phosphorylation, i itiated by 
the addition of a 25 ~tl sample, was carried out for 15 min at 25°C and 
stopped by the addition of ice-cold 10% TCA. PKC activity was calcu- 
lated as the difference of 32p incorporation i  the presence and absence 
of phosphatidylserine a d PMA. Each sample was assayed in duplicate 
and standardized tothe total cellular protein measured by the method 
of Bradford. 
2.2.4. Electrophoresis and immunoblotting. Cytosol and membrane 
fractions were prepared by centrifugation fhomogenate at 100,000 × g 
for 60 min. Proteins in homogenate, cytosol, and membranes were 
separated by SDS-PAGE and transferred to immobilon membranes. 
All values were standardized to the amount of protein measured by the 
method of Bradford. After blocking non-specific binding sites, the 
membranes were incubated with antiserum (1:400 to 1:1,000 dilutions) 
for 3C~60 min. Immunoreactive bands were visualized using alkaline 
phosphatase. Nonspecific binding was determined by omitting the pri- 
mary antibody or by preincubating with antibody blocking peptides. 
Rat brain was homogenized and used as a positive control. The speci- 
ficity of the PKC-~ antibody supplied by Dr. Parker has been published 
[16]. The amount of each PKC isozyme present was determined by 
densitometric scanning using a Computing Densitometer (Model 300A, 
Molecular Dynamics, Sunnyvale, CA) or an Image Analyzer (Biologi- 
cal Detection Systems, Pittsburgh, PA). 
3. Results 
3.1. Effect of cholinergic agonists on PKC-e 
Upon activation, PKC has been found to translocate 
from the cytosol to the plasma membrane [17]. Thus, 
translocation of PKC may serve as an indicator of its 
activation upon agonist stimulation. To determine if 
cholinergic agonists activate PKC, we investigated 
translocation of the Ca2+-independent isozyme PKC-e. 
Acini were incubated with 1 mM carbachol, and the 
amount of PKC-e in cytosol and membrane fractions 
was measured by immunoblotting. The basal PKC-e 
amount in control acini cytosol was 30.75 + 16.87 units/ 
gg protein (n = 4) (Fig. 1) and in control acini membrane 
was 14.75 + 4.90 units/fg protein (Fig. 1). A 5 s car- 
bachol stimulation significantly decreased the cytosolic 
PKC-e to 14.28 + 6.74 units/fg protein (n = 3; P < 0.05) 
and increased membrane-bound PKC-e to 25.82 + 8.25 
units/fig protein (P < 0.01) (Fig. 1). These results suggest 
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Fig. 1. Effect of carbachol on the intracellular distribution of PKC-e. 
The amount of PKC-e in cytosol and membrane fractions of lacrimal 
gland acini before (open bars) and after (solid bars) stimulation with 
10 -3 M carbachol for 5 s was measured by immunoblotting as described 
in section 2. Values are means +- S.E. (n = 3-4). *Significant difference 
from no added carbachol. 
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Fig. 2. Effect of PdBu treatment on protein kinase C isozymes. 
(A) Immunoblot of PKC-a, -6, and -E in lacrimal gland acini that had 
been untreated (0 h) or treated with PdBu for 20 min (0.3 h), 2 or 4 h. 
Acini were homogenized, polypeptides eparated, and PKC isozymes 
detected as described in section 2. 
that at least one isoform of PKC present in the lacrimal 
gland, PKC-E, might be activated by cholinergic ag- 
onists. 
3.2. Protein kinase C activity in PdBu-treated acini 
Long-term treatment of cells with phorbol esters re- 
sults in a loss of PKC activity. This is known as down- 
regulation of PKC and has been used to determine the 
role of this enzyme in different biological processes [181. 
Acini were treated for 2 h with PdBu at a concentration 
that caused maximum protein secretion (1 ,uM) . Total 
PKC activity was determined in PdBu-treated and un- 
treated acini. In PBDu-treated acini, the total PKC activ- 
ity in homogenate decreased by 80% to 59.7 pmol 32P/ 
min/mg protein from 294.8 pmol 32P/min/mg protein in 
untreated acini (Table 1). A second method to determine 
the efficiency of PKC down-regulation was to measure 
peroxidase secretion in PdBu-treated and untreated 
acini. In untreated acini, a 20 min incubation with PdBu 
(1 PM) stimulated secretion to 12.85 + 3.04 units/mg 
protein (Table 1). In PdBu-treated acini, peroxidase se- 
cretion was significantly inhibited by 82% to 2.38 f 2.20 
units (Table 1). A 3 h treatment with PdBu did not have 
Table 1 
Effect of 2 h PdBu (1 ,uM) treatment on PKC activity and on I ,uM 
PdBu-induced peroxidase secretion 
Control 
Treated 
PKC activity Peroxidase secretion 
(pm01 “P/min/mg protein) (units/min/mg protein) 
294.8 (2) 12.85 f 3.04 (4) 
59.7 (2) 2.38 + 2.20 (4)* 
Values are means f SE.; (n), no. of experiments. 
*P < 0.05. 
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Fig. 2 (B) Data from 6 separate xperiments as those shown in (A) are 
represented. 
any further effect (data not shown). These results demon- 
strate that lacrimal gland PKC can be effectively down- 
regulated by phorbol ester treatment. 
3.3. Effect of PdBu treatment on carbachol-induced 
peroxidase secretion 
To determine the role of PKC in cholinergic agonist- 
0 5 10 20 
The (lnin) 
Fig. 3. Effect of PdBu treatment on carbachol-induced peroxidase se- 
cretion. Lacrimal gland acini were pretreated for 2 h with 1 PM PdBu, 
then incubated with IO-’ M carbachol. Peroxidase secretion was meas- 
ured as described in section 2. open circles, control, filled circles, PdBu 
treated. values are means f S.E. (n = 4). *Significant difference from 
control. 
stimulated peroxidase secretion, acini with and without 
a 2 h PdBu treatment were stimulated for O-20 min with 
carbachol at a concentration that was maximal for per- 
oxidase secretion (lo-’ M) . In untreated cells, carbachol 
caused a rapid increase in peroxidase secretion from 0 to 
1 min and a slower, sustained secretion at 5 and 20 min 
(Fig. 3). A 2 h PdBu treatment significantly (P < 0.05) 
inhibited carbachol-induced secretion at 1 min by 
79% + 29%, by 35% & 13% at 5 min, but the effect was 
not significant; and significantly (P c 0.05) inhibited se- 
cretion by 66% & 20% at 20 min. Basal secretion in 
PdBu-treated acini was not significantly different from 
basal secretion in untreated acini at any time (data not 
shown). 
These results show that PKC plays a major role in the 
carbachol-induced lacrimal gland protein secretion. 
3.4. Effect of PdBu treatment on PKC isozymes 
Three PKC isoforms are present in rat lacrimal gland: 
PKC-a, -6, and -E ([12] and Fig. 2A). Each isozyme was 
present as a single polypeptide with the same molecular 
weight in both lacrimal gland acini and brain, except hat 
in one experiment PKC-6 was present as a doublet. In 
order to determine whether all three isoforms are equally 
down-regulated by PdBu treatment, lacrimal gland acini 
were treated with 1 ,LLM PdBu for 0, 20 min, 2 h, and 4 
h and the amount of each PKC isoform was quantified 
by immunoblotting. 
In cells treated with PdBu for 0 min, all three PKC 
isozymes were present. With a 20 min PdBu treatment, 
PKC-a: decreased by 31%, but PKCd and -E decreased 
by only 11% and 7%, respectively (Fig. 2B). With a 2 h 
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PdBu treatment PKC-a decreased by 36%, PKC-E de- 
creased by 2370, but PKC-6 decreased by only 3%. With 
a 4 h PdBu treatment PKC-a, -S, and -E decreased by 
50%, 37% and 37%, respectively. These results show that 
PKC-a is the most sensitive to down regulation while 
PKC-S is the least sensitive. PKC-E has an intermediate 
sensitivity. Moreover, taken together with the results in 
section 3.3., they suggest hat PKC-cx. and -E, but not 
PKC-6, are implicated in the secretory process. 
3.5. ESfect of PdBu treatment on [Cd+Ji 
In the lacrimal gland acini, carbachol induce an in- 
crease in [Ca2’li [6]. To determine if the 2 h PdBu treat- 
ment decreased cholinergic agonist-stimulated secretion 
by altering [Ca2’li, the carbachol-induced increase in 
[Ca*‘]i was measured in untreated and PdBu-treated 
acini. Basal [Ca’+], in untreated cells was 98.4 ? 19.9 nM 
(n = 4) and in PdBu-treated cells was 78.0 ? 13.1 nM; the 
difference is not significant. In untreated cells, a concen- 
tration of carbachol (10e3 M) that was maximal for in- 
creasing Ca” caused a rapid increase in the [Ca2+li, 
which decreased to a plateau value maintained for 16 
min (n = 4) (Fig. 4). In PdBu-treated acini, the car- 
bachol-induced Ca” response was not significantly dif- 
ferent from untreated cells at any time measured. 
These results rule out the possibility that phorbol ester 
treatment of lacrimal gland acini alters the cholinergic- 
induced increase in [Ca2’li, and demonstrate that inhibi- 
tion of carbachol-induced secretion is solely due to 
down-regulation of PKC by PdBu treatment. 
1 
Tim? (min) 
Fig. 4. Effect of PdBu treatment on intracellular [Ca”]. Lacrimal gland 
acini were pretreated for 2 h with I PM PdBu, then incubated with IO-’ 
M carbachol. [Ca”] was measured as described in section 2. Values are 
means f S.E. (n = 4). Data are presented as change in [Ca2’li over basal 
value. No significant difference was seen between PdBu treatment 
(filled circles) and no treatment (open circles). 
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4. Discussion 
Rat lacrimal gland protein secretion is mainly under 
the control of cholinergic muscarinic receptors [3,4]. Ac- 
tivation of these receptors leads to the production of two 
second messengers through the hydrolysis of phosphati- 
dylinositol4,Sbisphosphate by a phospholipase C [6,19]: 
IP, and DAG. To cause secretion, IP, liberates Ca2’ 
from intracellular stores and DAG activates PKC [1,2]. 
The role of Ca2’ in the control of protein secretion in the 
lacrimal gland has been well documented [20-221. PKC 
may play a role in this process as well. Mauduit et al. [ 131 
showed that PMA stimulates newly synthesized protein 
secretion in the lacrimal gland. Dartt et al. [14] showed 
that PdBu and OAG, a DAG analog, stimulate peroxi- 
dase secretion. Zoukhri et al. [ 121 showed that both PMA 
and PdBu stimulate newly synthesized protein secretion 
in the lacrimal gland. In contrast, three DAG analogs 
did not stimulate newly synthesized protein secretion and 
several inhibitors of PKC could not block the phorbol 
ester-induced secretion. Zoukhri et al. concluded from 
that study that PKC might not be the only effector of 
phorbol ester-induced protein secretion in the lacrimal 
gland [12]. 
The discrepancy between these studies might be due to 
the fact that wo different markers of protein secretion 
were used. In the Dartt et al. study, peroxidase secretion, 
i.e. one single protein as a marker of protein secretion 
was used. In the Zoukhri et al. report, tritiated protein 
secretion, i.e. newly synthesized proteins was employed. 
It is likely that the mechanisms involved in the control 
of peroxidase secretion versus newly synthesized protein 
secretion are different since newly formed granules are 
preferentially liberated upon stimulation. 
Concerning the role of PKC in receptor-mediated pro- 
tein secretion in the lacrimal gland, Dartt et al. showed 
that cholinergic agonists cause a transient, although not 
significant, decrease in cytosolic PKC activity [7]. This 
suggested that PKC might be involved in cholinergic- 
induced peroxidase secretion. In the present study, we 
show that cholinergic agonists induce a rapid (5 s) 
translocation of PKC-E from the cytosol into the mem- 
brane fraction (Fig. I). Translocation of PKC has been 
described in a variety of tissues and cell lines and has 
been considered as a primary step to PKC activation [2]. 
Long-term treatment of cells with phorbol esters has 
been shown to partially, or completely deplete cellular 
PKC [23]. This phenomenon is known as desensitization 
or down-regulation of PKC and has been widely used to 
study the role of PKC in the control of different proc- 
esses [18]. In the present study, we used PdBu to down- 
regulate PKC. We found that a 2 h treatment with phor- 
bol esters resulted in an 80% decrease in PKC activity 
(Table 1). Moreover, the decrease in PKC activity in 
PdBu-treated acini correlated well with the decrease in 
PdBu-induced peroxidase secretion in these cells (Table 
1). This decreased secretion might be due to depletion of 
peroxidase from acini with the 2 h PdBu treatment. This 
is unlikely because phenylephrine, an a,-adrenergic ag- 
onist, still causes peroxidase secretion in PdBu treated 
acini [24]. Moreover, PdBu treatment increased phenyle- 
phrine-induced peroxidase secretion [24]. These results 
strongly suggest hat PKC activity is effectively down- 
regulated by phorbol ester treatment and are in agree- 
ment with Tan and Marty [25] who reported that a 224 
h treatment of lacrimal gland acinar cells with PMA 
down-regulated PKC. 
We then used a 2 h PdBu treatment o study the role 
of PKC in cholinergic-induced peroxidase secretion. We 
found that such a treatment results in a decrease of car- 
bachol-induced protein secretion measured at three time 
points (79% decrease at 1 min, 35% at 5 min, and 66% 
at 20 min). These results suggest hat PKC appears to 
play a major role in cholinergic-induced protein secre- 
tion. 
Activation of lacrimal gland cholinergic receptors 
leads to an increase in cytosolic [Ca”] [6]. In order to 
verify that phorbol ester treatment did not affect the 
increase in [Ca”] induced by cholinergic agonists, we 
compared the effect of carbachol on [Ca”] in both un- 
treated and PdBu-treated acini. Our results show that the 
response to carbachol in control acini was indistinguish- 
able from that in treated acini (Fig. 4). We can then 
conclude that the decrease in carbachol-induced secre- 
tion in phorbol ester-treated acini is not due to altered 
response in [Ca”] but only to down-regulation of PKC. 
As there are three isoforms of PKC present in the 
lacrimal gland: PKC-a, -6, and -E ([12] and Fig. 2A), we 
conducted experiments to determine if all three isoforms 
were equally sensitive to down-regulation. Using specific 
antibodies against these isoforms, we found that PKC-a 
is very sensitive to proteolysis as 31% of the protein was 
lost 20 min after application of PdBu. At the same time- 
point, PKC-8 and -E were only slightly decreased (11 and 
7%, respectively) (Fig. 2B). A 2 h PdBu treatment, a time 
point that resulted in effective decrease of PKC activity 
(80%) and peroxidase secretion (82%) PKC-a was down 
by 36%, PKC-E by 23%, whereas PKC6 was decreased 
by only 3% (Fig. 2B). These results suggest hat PKC-a 
and -E, but not PKCd, are implicated in the cholinergic- 
induced peroxidase secretion in the lacrimal gland. 
We conclude that PKC-a , -6, and -E present in the 
lacrimal gland are unequally down-regulated by phorbol 
esters with PKC-a being the most sensitive and PKC-6 
being the least sensitive, and that PKC-a and -E, but not 
-6, play a role in cholinergic-induced protein secretion. 
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